Managing prostate cancer

the role of hormone therapy.

Michelle L. Ramirez, Thomas E. Keane, Christopher P Evans

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Androgen deprivation therapy has been the mainstay of treatment for men with metastatic prostate cancer and now plays a more active role in the management of less advanced cancers as neoadjuvant and adjuvant treatment. Investigative uses include primary therapy for patients unsuitable for definitive therapy and as a complement to ablative procedures, brachytherapy, and chemotherapy. Intermittent androgen deprivation therapy is being considered as an alternative to continuous therapy and further evaluated as triple androgen blockade in conjunction with finasteride. Many accepted and potential management schemes incorporating hormonal therapy are increasingly employed despite indeterminate indications for use. Here, we review currently available data on the efficacy of hormonal therapy with regard to complete androgen ablation, primary, neoadjuvant, and adjuvant therapy. Additionally, we examine the usefulness of delayed versus immediate administration, intermittent androgen deprivation, and other prospective applications for hormonal therapy.

Original languageEnglish (US)
Pages (from-to)10-18
Number of pages9
JournalThe Canadian journal of urology
Volume14 Suppl 1
StatePublished - Dec 2007

Fingerprint

Prostatic Neoplasms
Hormones
Androgens
Neoadjuvant Therapy
Therapeutics
Finasteride
Brachytherapy
Drug Therapy
Neoplasms

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Managing prostate cancer : the role of hormone therapy. / Ramirez, Michelle L.; Keane, Thomas E.; Evans, Christopher P.

In: The Canadian journal of urology, Vol. 14 Suppl 1, 12.2007, p. 10-18.

Research output: Contribution to journalArticle

Ramirez, Michelle L. ; Keane, Thomas E. ; Evans, Christopher P. / Managing prostate cancer : the role of hormone therapy. In: The Canadian journal of urology. 2007 ; Vol. 14 Suppl 1. pp. 10-18.
@article{3ed0c33252644dfc9d87c2f156ee1139,
title = "Managing prostate cancer: the role of hormone therapy.",
abstract = "Androgen deprivation therapy has been the mainstay of treatment for men with metastatic prostate cancer and now plays a more active role in the management of less advanced cancers as neoadjuvant and adjuvant treatment. Investigative uses include primary therapy for patients unsuitable for definitive therapy and as a complement to ablative procedures, brachytherapy, and chemotherapy. Intermittent androgen deprivation therapy is being considered as an alternative to continuous therapy and further evaluated as triple androgen blockade in conjunction with finasteride. Many accepted and potential management schemes incorporating hormonal therapy are increasingly employed despite indeterminate indications for use. Here, we review currently available data on the efficacy of hormonal therapy with regard to complete androgen ablation, primary, neoadjuvant, and adjuvant therapy. Additionally, we examine the usefulness of delayed versus immediate administration, intermittent androgen deprivation, and other prospective applications for hormonal therapy.",
author = "Ramirez, {Michelle L.} and Keane, {Thomas E.} and Evans, {Christopher P}",
year = "2007",
month = "12",
language = "English (US)",
volume = "14 Suppl 1",
pages = "10--18",
journal = "Canadian Journal of Urology",
issn = "1195-9479",
publisher = "Canadian Journal of Urology",

}

TY - JOUR

T1 - Managing prostate cancer

T2 - the role of hormone therapy.

AU - Ramirez, Michelle L.

AU - Keane, Thomas E.

AU - Evans, Christopher P

PY - 2007/12

Y1 - 2007/12

N2 - Androgen deprivation therapy has been the mainstay of treatment for men with metastatic prostate cancer and now plays a more active role in the management of less advanced cancers as neoadjuvant and adjuvant treatment. Investigative uses include primary therapy for patients unsuitable for definitive therapy and as a complement to ablative procedures, brachytherapy, and chemotherapy. Intermittent androgen deprivation therapy is being considered as an alternative to continuous therapy and further evaluated as triple androgen blockade in conjunction with finasteride. Many accepted and potential management schemes incorporating hormonal therapy are increasingly employed despite indeterminate indications for use. Here, we review currently available data on the efficacy of hormonal therapy with regard to complete androgen ablation, primary, neoadjuvant, and adjuvant therapy. Additionally, we examine the usefulness of delayed versus immediate administration, intermittent androgen deprivation, and other prospective applications for hormonal therapy.

AB - Androgen deprivation therapy has been the mainstay of treatment for men with metastatic prostate cancer and now plays a more active role in the management of less advanced cancers as neoadjuvant and adjuvant treatment. Investigative uses include primary therapy for patients unsuitable for definitive therapy and as a complement to ablative procedures, brachytherapy, and chemotherapy. Intermittent androgen deprivation therapy is being considered as an alternative to continuous therapy and further evaluated as triple androgen blockade in conjunction with finasteride. Many accepted and potential management schemes incorporating hormonal therapy are increasingly employed despite indeterminate indications for use. Here, we review currently available data on the efficacy of hormonal therapy with regard to complete androgen ablation, primary, neoadjuvant, and adjuvant therapy. Additionally, we examine the usefulness of delayed versus immediate administration, intermittent androgen deprivation, and other prospective applications for hormonal therapy.

UR - http://www.scopus.com/inward/record.url?scp=40349085836&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=40349085836&partnerID=8YFLogxK

M3 - Article

VL - 14 Suppl 1

SP - 10

EP - 18

JO - Canadian Journal of Urology

JF - Canadian Journal of Urology

SN - 1195-9479

ER -